Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration

Brain autopsy and biomarker studies indicate that the pathology of Alzheimer’s disease (AD) is initiated at least 10–20 years before clinical symptoms. This provides a window of opportunity to initiate preventive treatment. However, this emphasizes the necessity for biomarkers that identify individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Höglund, K, Kern, S, Zettergren, A, Börjesson-Hansson, A, Zetterberg, H, Skoog, I, Blennow, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545720/
https://www.ncbi.nlm.nih.gov/pubmed/28072416
http://dx.doi.org/10.1038/tp.2016.252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545720/
https://www.ncbi.nlm.nih.gov/pubmed/28072416
http://dx.doi.org/10.1038/tp.2016.252

Ejemplares similares